INTRODUCTION
Filariasis is a group of infectious diseases caused by arthropod-borne nematodes. Several of these parasites, most notably Onchocerca volvulus, Brugia malayi, and Wuchereria bancrofti, are important causes of diseases in humans. Infection is common in many areas of the tropics and constitutes a major public health problem in several geographic regions such as the Indian subcontinent and the South Pacific. In the past few years, attention has been focused on understanding the biological and medical aspects of these diseases, using the newer technologies and analytical approaches of immunology and molecular biology. The present review is intended to summarize the recent advances in these fields as they apply to the diagnosis and control of human filariasis. Because of the relatively greater number of experimental studies of lymphatic filariasis compared with those of onchocerciasis and loaiasis, the former infection will be discussed in greater detail. malayi (20) .
VECTOR-PARASITE RELATIONSHIPS Arthropod Vectors
The known mosquito vectors of W. bancrofti, B. malayi, and B. timori belong to four main genera: Anopheles, Aedes, Culex, and Mansonia (127) . The efficiency of specific mosquito species to transmit filarial infection to humans is determined by multiple factors. Some species do not transmit the parasite because ingested microfilariae fail to develop to infective forms in the insect. Some mosquitoes may be poor vectors because their population density is too low or simply because they do not bite humans; i.e., they either are autogenous or feed extensively on other animals. Several reviews describing the relationship of mosquito vectors to transmission of human lymphatic filariasis have been published (83, 144) . A large body of information on the taxonomy, bionomics, and control of mosquito populations is available (84) .
The bionomics and taxonomy of Onchocerca vectors have been extensively reviewed (18, (74) (75) (76) 88 (53) (54) (55) (56) 130) . They can be classified into two general groups on this basis: (i) the nocturnally periodic strain and (ii) the nocturnally subperiodic strain. The former have peak concentrations from 2200 to 0200 h; no or very few parasites are detectable in peripheral blood during the daytime hours. The nocturnally subperiodic strains also exhibit their highest levels of parasitemia at night, but 40 to 60% of peak levels persist during the day. In addition to these two basic strains, a third form, the nonperiodic or diurnally subperiodic, in which there is little variation with time of day has been described (27, 52 (17) .
There is only scant knowledge of the biosynthetic pathways of nucleic acids and lipids in filarial nematodes, primarily because of a lack of fully defined and successful in vitro culture conditions that permit expression of the complete parasite life cycle. Studies by Longworth et al. have shown that B. malayi microfilariae and adult worms incorporate exogenous long-chain fatty acids such as arachidonic, palmitic, oleic, and linoleic acids (77, 78) . Arachidonic acid is rapidly esterified into phospholipids including phosphatidylinositol. Esterification of other fatty acids into phospholipids is quantitatively less and involves incorporation into phosphatidylcholine and phosphatidylethanolamine. Recent experiments indicate that microfilariae may metabolize host platelet eicosanoids in a manner which leads to production of biologically active lipids such as 12-hydroxyeicosatetraenoic acid (L. Liu and R. F. Weller, Clin. Res. 36:461, 1988 ). Jaffe and Chrin (61) have shown that B. pahangi and Dirofilaria immitis microfilariae carry out purine synthesis de novo. These parasites also possess purine salvage pathways. It is not clear why two separate routines for purine synthesis coexist in these organisms. In vitro studies demonstrate that adult filarial nematodes including B. pahangi, 0. volvulus, and A. viteae rapidly take up glucose via a transcuticular route (114) . These parasites rely heavily on glycolysis for energy production, and 10 to 20% of the glucose taken up is converted to glycogen. In B. pahangi and A. viteae, the primary product of metabolism is lactate, indicating that the worms are primarily homolactate fermenters (138) . The release of small amounts of succinate suggests that a partially reversed tricarboxylic acid cycle is also active in these filarial nematodes (114) .
Oxygen consumption and oxidative phosphorylation may represent important metabolic facets of filarial nematodes. Low oxygen tension is required for in vitro growth, molting, and differentiation of B. pahangi and A. viteae (40) . Measurable rates of exogenous oxygen uptake have been demonstrated for adult A. viteae, Dirofilaria immitis, and B. pahangi. However, cytochrome c and cytochrome c oxidase were not detected in these systems. Mendis and Townson demonstrated the presence of a classical respiratory electron transport sequence in adult B. pahangi and A. viteae (87) .
Another aspect of filarial metabolism which needs further study is the toxic nature of oxygen for these organisms. Scavenger enzymes such as catalase, superoxidase dismutase, and glutathione peroxidase and vitamins such as vitamin C and ascorbic acid are important antioxidants (142) . Several investigators have reported the uptake and existence of retinol (vitamin A) as well as its formation from betacarotene in 0. volvulus and B. pahangi. The retinyl phosphate formed from retinol may be involved in glycoprotein synthesis (14) .
The mechanisms by which filarial worms penetrate and migrate within host tissues remain largely unknown. 0. volvulus and B. malayi contain and release proteolytic enzymes that solubilize collagen molecules from native type I collagen fibers (108) . Further studies are needed to characterize and determine the role of proteases in the life cycle of the parasite. W. bancrofti infection exists in greatest numbers in tropical and subtropical Asia, Africa, and the South Pacific. Caribbean nations, such as Haiti, and coastal areas of Brazil are also endemic foci, generally with lower intensities of infection than those observed in Asian countries. B. malayi infection is limited to southern China, Malaysia, the Philippines, and a few areas of India. B. timori infections occur only on the Indonesian islands of Timor and Flores (20) . It has been estimated that -90 million people worldwide are infected with lymphatic filariae (96 (132) . In the absence of these or other peculiarities, however, a general pattern of infection is observed in many endemic areas. Patent microfilaremia is first detected in 5 to 10 year olds, the prevalence ranging from <10% in regions where transmission is low to >20% where transmission is intense (e.g., some rural areas of Papua New Guinea) (20, 21, 66, 115 The most consistent finding of studies conducted in several endemic areas is marked suppression of cell-mediated immunity to mitogens (110) and filarial antigens (109, 112) . This phenomenon has been reported in both bancroftian and brugian filariasis and has been demonstrated reproducibly as a reduction in in vitro T-lymphocyte blastogenesis in response to crude parasite extracts. The basis for this alteration in immune reactivity is not related to an inability of target lymphocytes to respond but to the presence of suppressor mononuclear cells (112) . Correlation of these responses with microfilarial status and longitudinal studies of individuals before and after administration of antimicrofilarial chemotherapy indicates that high "microfilarial burdens" result in diminished and actively suppressed immunity to filarial antigens (113) . These responses may benefit not only the parasite by allowing it to escape damage by host immune mediators but also the infected individual, who may temporarily avoid the pathologic consequences of immune reactivity. The recent development of a nude mouse model of lymphatic inflammation associated with Brugia infection (134) and measures of granulomatous reactions in jirds (62) should be useful in assessing the veracity of this concept. In addition, identification of the specific filarial antigens which elicit and modulate T-cell responses will be helpful in designing methods to control undesirable consequences of cellmediated immunity. The recent description of T-cell clones responsive to filarial extracts (93) and identification of several 0. volvulus complementary DNA clones encoding polypeptides that drive lymphocyte proliferation of cells from infected donors (131) should aid in dissecting this important aspect of immunity.
An exceedingly complex humoral immune response to filarial parasites develops during the course of infection. Unlike bacteria and most unicellular pathogens, multiple stages of filariae may simultaneously exist in the host. Each may contain distinct antigens that are not only displayed on the parasite surface but also released as metabolic products (71, 82) . These molecules elicit high titers of immunoglobulin M (IgM), IgG, and IgE antibodies, especially in amicrofilaremic individuals (59, 83, 97) . Although IgE antibodies are generally associated with allergic responses, such clinical reactions are uncommon in persons residing in endemic areas. This may in part be related to concurrent development of IgG "blocking" antibodies (59, 60, 102) . Recent studies of Hussain and co-workers (58) demonstrate that specific subclasses of IgG antibody may be involved in determining the outcome of infection. IgG4 antibodies were present in significantly higher titers in asymptomatic microfilaremic subjects than in symptomatic amicrofilaremic persons with elephantiasis. These antibodies did not react with a restricted set of filarial antigens in immunoblotting studies but rather with molecules of 10,000 to >100,000 Mr. Elucidation of this aspect of the immune response will be facilitated by continued efforts to purify and define the stage specificity of native antigens (10, 71) that drive B-lymphocyte responses (70, 91) and to clone immunologically relevant antigens (2, 121, 147) .
To date, protective immunity in human lymphatic filariasis has not been proven. However, epidemiologic surveys described in a previous section of this review and experimental studies in animal models of filariasis (20, 57, 64, 65, 95, 141) suggest that partial resistance to filarial infection may develop Lymphatic filariasis. The spectrum of disease manifestations of lymphatic filariasis has been described in a practical and clinically useful manner by Ottesen (96, 98) . At one extreme, residents of endemic areas are amicrofilaremic and lack disease attributable to lymphatic filariasis. It is presumed that these subjects are exposed to infective larvae with a frequency similar to that of other persons residing in the same endemic region. Such individuals may be "partially" resistant to infection and exhibit high lymphocyte proliferative responses to filarial antigens. Next in degree of severity are asymptomatic subjects with microfilaremia. Many (26) . Individuals with these severe disease manifestations are usually amicrofilaremic, although microfilaremia may persist in persons living in areas where transmission is intense. Persons with these severe disease manifestations tend to have relatively high antimicrofilarial antibody titers (85) and vigorous lymphocyte proliferative responses to antigens derived from adult-stage parasites (110) .
At the opposite end of the spectrum from amicrofilaremic asymptomatic subjects are persons with the tropical eosinophilia syndrome. Hypersensitivity responses predominate early during the course of filarial infection in persons with tropical eosinophilia (101) . The syndrome occurs most commonly in restricted geographic regions such as southern India and is characterized by extreme elevations of serum IgE (>5,000 U/ml), high IgE and IgG anti-microfilarial antibody titers, amicrofilaremia, nocturnal asthmatic symptoms, and eosinophilia. Administration of diethylcarbamazine (DEC) results in prompt clinical resolution of symptoms. If tropical eosinophilia syndrome remains untreated, chronic restrictive pulmonary disease may develop. The pathologic response in tropical eosinophilia syndrome is likely secondary to local immune reactivity to microfilariae in the pulmonary vasculature (101) . Eosinophil accumulation in the lung and release of potentially toxic molecules such as cationic proteins and reduced oxygen products may cause tissue damage, with subsequent fibrosis.
Onchocerciasis. The major clinical signs of onchocerciasis include dermatitis, subcutaneous nodules, lymph node enlargement, and eye disease (1, 128) . Skin disease is most frequently manifest as pruritus with excoriations secondary to scratching. Erythema is also seen in many individuals. If infection persists, elastic fibers are gradually lost, with consequent skin wrinkling and atrophy (16) . Hypo-and hyperpigmentation of the skin are especially common in individuals living in the rain forest areas of Africa (1). Skin biopsies of asymptomatic or mild cases reveal microfilariae in the upper epidermis with scant cellular reaction. Mononuclear cells and eosinophils are present in specimens obtained from persons with persistent disease and in those to whom antimicrofilarial chemotherapy has recently been given (15, 16) . Inflammatory cells are localized around blood vessels and in dermal appendages. Subcutaneous nodules or onchocercomata contain adult worms. These nodules are painless and several centimeters in diameter and tend to be localized near the pelvis in Africans and the upper torso and head in Central Americans. The lesions consist of an outer border of scar tissue surrounding adult worms, eosinophils, and mononuclear cells (68, 81) . Older onchocercomata may calcify, become firm to palpation, and contain necrotic material. In 0. volvulus infection, lymphatic disease is less common than in filariasis and tends to occur in the inguinal and femoral areas in Africans. In its most severe degree, pendulous lesions known as "hanging groin" may develop. These consist of a massively enlarged lymph node and surrounding edematous skin (42) . Ocular disease is the most devastating manifestation of onchocerciasis and accounts for its colloquial name, river blindness. It is one of the leading preventable causes of blindness worldwide (44, 81, 88, 119 (23) .
Microfilariae of 0. volvulus are usually detected in the skin and the eye, although heavily infected individuals may occasionally harbor the organisms in blood or urine. To examine skin for microfilariae, blood-free biopsies are obtained from the interscapular region and gluteal area of Africans and deltoids of Central Americans (36, 44) . This is done with a scleral punch or sharp razor blade and should be almost painless when done quickly. The specimen is then weighed, placed in a small volume of culture medium (e.g., RPMI 1640) or saline, and allowed to incubate for several hours. Microfilariae that have emerged from the skin are counted by inspection under a dissecting microscope. Provocative tests utilizing DEC to induce itching and erythema (i.e., Mazzotti reaction) should not be done since this may precipitate ocular disease (47) . Demonstration of microfilariae in the eye usually requires the aid of a slit lamp. Tilting the patient's head forward for several minutes before examination increases the probability of detecting microfilariae in this location. Direct examination of the eye with an ophthalmoscope may reveal microfilariae in fluffy opacities in the cornea.
Serologic Assays
The inherent insensitivity of parasitologic methods for diagnosis of infection in persons with no or low intensities of microfilariae in blood or subcutaneous tissue has prompted the development of serologic assays. As is the case with other infectious diseases, the presence of serum antibodies, especially when obtained at one time point only, does not reliably distinguish between past infection and active infection, in which live adult filariae are present. Several investigators have measured circulating antigen levels to detect infection in amicrofilaremic patients and possibly as an indirect index of adult-worm burden (39, 143) . The Gib 13 and BP-1 monoclonal antibody-based assays were found to detect infection in a portion of amicrofilaremic adults (39, 82) . These assays are not specific for lymphatic filariasis, however, as the monoclonal antibodies utilized to trap serum antigen were subsequently determined to be directed against phosphocholine epitopes (72) . Phosphocholine is found in several other infectious agents (50, 107) . Other antigens such as those shared with the dog heartworm Dirofilaria immitis have also been tested in the field (140), but to date none have proven to be both specific and sensitive enough for general use.
The development of circulating antigen assays for onchocerciasis has proven to be even more problematic than for lymphatic filarial infections, because of the relatively high levels of circulating immune complexes which develop in the infection (22) . DNA probes which are sensitive and specific for the filarial species of interest have recently been developed and may represent a diagnostic approach superior to antibody-or antigen-based methods (37, 86, 106, (122) (123) (124) .
CHEMOTHERAPY OF HUMAN FILARIASIS DEC has been the standard chemotherapy for all forms of human filariasis. Recent studies with the macrocyclic lactone ivermectin, an agent widely used in veterinary medicine, indicate that this drug is significantly safer and at least as effective as DEC in the treatment of onchocerciasis. Ivermectin may also have some advantages over DEC in the chemotherapy of lymphatic filariasis. It should be noted in discussions of currently available agents active against these two major classes of filariae that they are unlikely to have a beneficial effect in individuals with severe eye disease or long-standing lymphatic obstruction.
Lymphatic Filariasis DEC acts primarily as a microfilaricidal drug (80, 99) . Its mechanism of action remains ill defined, although multiple studies suggest that host immune reactivity to microfilariae is modified after administration of the drug and may be required for its antiparasite activity (80, 113) . Adult worms of W. bancrofti are most likely unaffected by conventional doses of DEC. B. malayi adult parasites appear to become necrotic after administration of the drug to humans (80) .
A variety of dosage regimens have been used. A cumulative dose of 72 mg/kg of body weight given over a 2-to 3-week period is successful in reducing the intensity of microfilaremia by >90% for a period of 6 to 12 months (116, 117) . Practical problems with administration of DEC in this manner to large populations in tropical areas of the world has led to testing several alternative schedules, including a medicated salt form and lower doses as prophylaxis (4, 67, 96, 116) . Long-term weekly administration to a total dosage that may kill adult worms (e.g., 144 mg/kg) has also been proposed (99) . These regimens require further testing in the field.
Toxicity from DEC is of two general types. Direct toxicity is dose related, manifested as nausea and vomiting, and related to central nervous system effects of DEC (116, 117) . Toxicity occurs in uninfected as well as infected individuals and can be avoided by giving the drug in smaller, divided, daily doses. The other major form of toxicity occurs in infected persons only and appears to be secondary to death of microfilariae. The symptoms include fever, nausea and vomiting, headache, prostration, and, in the most severely affected individuals, asthmatic attacks. These may appear within 1 to 2 days of initiating therapy and occur concomitantly with an acute drop in microfilaremia (12, 13) . Their severity is minimized by initiating therapy with approximately one-quarter of the calculated dose and gradually reaching full doses after 3 to 4 days.
Direct comparisons of the efficacy of ivermectin and DEC in the treatment of lymphatic filariasis have not yet been performed in large numbers of individuals in various endemic areas. However, preliminary data reported from India and the South Pacific suggest that ivermectin has microfilaricidal activity equivalent to DEC and fewer side effects and that it is easier to administer (single oral dose) (24) .
Onchocerciasis DEC was used for many years to treat 0. volvulus infection and had well-known side effects, including pruritus, lymphadenitis, fever, and, more seriously, hypotension, keratitis, and optic neuritis (44, 80) . Since the pathologic response in onchocerciasis is related primarily to host reactions to microfilariae and since complications of DEC therapy include acute visual impairment (48) , there has been an urgent need to identify effective and safe microfilaricidal drugs for this infection. Initial trials with ivermectin without comparison to other drugs (3) have been followed by direct comparisons of ivermectin to standard therapy with DEC (48) . These vug/kg of body weight given once by the oral route reduces the intensity of microfilaridermia by >90% 1 to 6 months after administration. Optimal doses and frequency of administration to prevent development of ocular or skin disease manifestations remain to be established. Loajasis DEC is currently the primary drug used to treat L. loa infection. It appears to not only eliminate microfilariae but also kill adult worms. The drug is given at a dose of 8 to 10 mg/kg of body weight per day for 14 to 21 days. Repeated courses of DEC may be required in some individuals. It is important to note that in heavily infected persons microfilariae may migrate to the central nervous system during DEC therapy and cause meningoencephalitis and coma. These persons should be treated initially with lower doses of DEC (e.g., 1 mg/kg for 3 to 5 days) in combination with corticosteroids (96) .
FUTURE DIRECTIONS
Major advances in our understanding of several aspects of filariases will ultimately lead to improved means of controlling these helminthic infections. First, with respect to epidemiology, efforts should be continued to develop specific and sensitive assays of parasite antigen that reflect adult worm load. Knowledge of this parasitologic index will permit accurate longitudinal assessment of the impact of vector eradication, chemotherapy, and vaccine programs. Emphasis should also be placed on the development of chemotherapy that kills adult worms of 0. volvulus, W. bancrofti and B. malayi. More detailed understanding of the biochemical pathways unique to this parasite stage and not present in the mammalian host may provide a fruitful approach for the design of drugs. Finally, an understanding of the immunopathologic and protective role of B-and T-cell responses to specific parasite antigens will ultimately underlie the development of a vaccine to eradicate or control the infection in endemic areas. Based on studies of other helminthic infections, emphasis should be placed on defining epitopes that elicit T-cell helper or inducer responses and IgE antibodies. 
